Lissun Raises Rs 48 Crore to Expand Care for Children with Developmental Needs
Lissun, a single-specialty health-tech platform focused on children with special needs and developmental delays, has raised Rs 48 crore in a Series A funding round led by Colossa Ventures. The round saw participation from Physis Capital and existing investors including RPSG Capital Ventures, Ivycap Ventures, Rainmatter, Multiply Ventures and SucSEED Ventures. New investors New Age India Fund and Beyond Capital Ventures also joined the round.
The Gurugram-based startup had earlier raised $2.5 million in a pre-Series A round led by RPSG Capital Ventures in September 2024. It also secured Rs 2.77 crore from Zerodha and other investors in June this year. The latest capital will support the expansion of Sunshine by LISSUN centres in key cities, the development of AI-led solutions using proprietary technology and data, and the strengthening of clinical processes across its network.
Addressing a Critical Gap in Child Development Care
India is seeing a growing need for advanced developmental and behavioural care for children. Conditions such as autism, ADHD, and speech and language disorders require early identification and consistent, high-quality intervention. Yet access to such care remains limited and fragmented in many parts of the country.
Lissun aims to bridge this gap through its child-care brand, Sunshine by LISSUN. The platform brings together trained therapists and an AI-supported ecosystem that works both at physical centres and through digital tools. The goal is to make structured, evidence-based developmental support more accessible and consistent for families.
Founding and Operating Model
Lissun was founded in 2021 by Krishna Veer Singh and Tarun Gupta. The company operates through a combination of physical child development centres and digital products. Sunshine by LISSUN centres provide therapy and developmental support, while AI-led tools and digital offerings extend the reach of care beyond the centres themselves.
This hybrid model allows the company to serve families who can access in-person services while also building scalable digital solutions for a much larger population. By combining clinical expertise with technology, Lissun seeks to standardise quality and improve outcomes over time.
Growth and Current Scale
The company reports that it has grown fourfold over the past year. It currently conducts more than 10,000 therapy sessions each month across 25 centres. These numbers indicate meaningful traction in a sector where trust, clinical quality and consistency are critical.
Looking ahead, Lissun plans to expand its physical network to 50 centres by next year. On the digital side, the company aims to reach more than 10 lakh children over the coming years through its products and tools. Achieving this will depend on both geographic expansion and the effective use of technology to support screening, therapy guidance and ongoing engagement with families.
Use of Fresh Capital
The Series A funds will be deployed across three main areas. First, the company will expand Sunshine by LISSUN centres in key cities, increasing the number of locations where families can access in-person developmental support. Second, it will invest in AI-led solutions built on its proprietary technology and data. These tools are intended to enhance clinical decision-making, personalise interventions and improve operational efficiency. Third, Lissun will strengthen clinical processes across its network to maintain quality as it scales.
For a business operating in paediatric developmental care, maintaining clinical standards while growing is essential. The emphasis on both physical expansion and technology development reflects an attempt to balance reach with consistency.
Competitive Landscape
Lissun operates in a specialised but increasingly active segment of health-tech. It competes with platforms such as Butterfly Learnings, Continua Kids, Hoola Health and Children First from Amaha. These companies work across different parts of the continuum, including early screening, diagnosis support, therapy and longer-term developmental care.
The broader single-specialty space focused on children with special needs has attracted investor attention. Butterfly Learnings raised Rs 32 crore in Series A funding in 2024. CureAble secured Rs 2 crore in pre-seed funding in 2025, while Gabify raised $175,000 in pre-seed funding in 2026. More recently, paediatric healthcare platform Hoola Health raised $5 million in 2026 and offers developmental assessments and therapy services as part of its child-focused model.
This activity suggests growing recognition of the need for structured solutions in paediatric developmental and behavioural care, even as the market remains relatively early and fragmented.
The Road Ahead
With the Series A closed, Lissun enters a phase focused on scaling both its physical presence and its technology capabilities. Expanding to 50 centres will require careful site selection, therapist recruitment and training, and the ability to replicate clinical processes across locations. At the same time, developing AI-led tools that genuinely support therapists and families will be critical to differentiating the platform and extending its impact beyond the centres.
The company’s progress will depend on its ability to deliver measurable outcomes for children, maintain the trust of parents, and operate efficiently at larger scale. In a category where care quality and consistency matter deeply, execution on both the clinical and technological fronts will determine how effectively Lissun can help close the gap in developmental support for children across India. The Rs 48 crore raise provides the resources to test that ambition more broadly in the years ahead.